Search results
Fans can finally get a chance to listen to the Wu-Tang Clan’s one copy album… but there’s a catch |...
CNN.com· 22 hours ago“Once Upon a Time in Shaolin” is as mysterious as its title. Recorded by legendary hip-hop group...
Quadrant Capital Group LLC Purchases 1,330 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)
ETF DAILY NEWS· 2 days agoQuadrant Capital Group LLC lifted its position in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 1,117.6% in the 4th quarter, Holdings Channel reports ...
2 Stocks That Could 10x by 2035
Motley Fool via Yahoo Finance· 6 days agoUnder this scenario, the biotech could indeed 10x in the next 10 years. 2. Recursion Pharmaceuticals The biotech industry seems to be ...
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar...
Zacks via Yahoo Finance· 5 days agoStocks recently featured in the blog include: Biogen BIIB, IonisPharmaceuticals IONS, GSK plc GSK,...
TD Cowen expects Medpace to 'outpace large pharma', initiates buy rating on stock By Investing.com
Investing.com· 12 hours agoThe firm assigned a Buy rating to Medpace, accompanied by a price target of $452.00. The coverage...
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
Zacks· 7 days agoWith the end of the first-quarter earnings season, the focus has now shifted to pipeline and regulatory updates. Mergers and acquisitions continue to be in the spotlight as pharma and
Activation Capital Introduces 'Frontier BioHealth' to Catalyze Life Science Startups
FOX 59 Indianapolis· 6 days agoIt will broaden the continuum of regional early-stage support – additive to Virginia Commonwealth...
Corcept (CORT) Rises as Cushing's Syndrome Study Meets Goal
Zacks via Yahoo Finance· 9 hours agoCorcept's (CORT) phase III GRACE study, evaluating its lead candidate, relacorilant, for treating...
BMS stakes $80m on Prothena’s neurodegenerative candidate
Pharmaceutical Technology via Yahoo Finance· 12 hours agoThe biotech cited higher R&D and G&A expenses in 2023 compared to the previous year. Prothena’s most...
Insmed shares double as lung drug data convince Wall Street
BioPharma Dive via Yahoo Finance· 2 days agoAfter reporting positive clinical trial results for its drug brensocatib, Insmed plans to later this...
